Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCA 33890 (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Muzastotug; Oxaliplatin
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Malignant melanoma; Malignant-mesothelioma; Mouth neoplasm; Non-small cell lung cancer; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Sarcoma; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Incyte Corporation

Most Recent Events

  • 23 Jul 2026 Protocol amended to add combination therapy arm with ADG126. Number of Arms increased to 12.
  • 23 Jul 2026 Planned End Date changed from 13 Jan 2027 to 3 May 2029.
  • 23 Jul 2026 Planned primary completion date changed from 13 Jan 2027 to 3 May 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top